In an attempt to reduce the incidence and severity of acute graft-versus-host disease (GVHD), we have decreased the number of bone marrow (BM) lymphocytes in the donor marrow graft before bone marrow transplantation (BMT) using counterflow centrifugal elutriation (CCE). In a phase 1-11 clinical trial, 23 patients received lymphocyte-depleted BM allografts from their HLA-identical, mixed lymphocyte culture (MLC)-nonreactive sibling donors. The patients entered in the study were deemed to be at high risk for treatment failure on the basis of age (greater than 30 years; median, 39 years) and the result of our skin explant assay predictive of acute GVHD. Patients predicted not to develop acute GVHD by this assay were excluded from this study. All patients received a standard lymphocyte dose of 0.5 x lo'morphologic lymphocytes per kilogram ideal body weight (IBW) in the marrow graft and were maintained on cyclosporine A (CsA) immunosuppression for 170 days after BMT. Prompt hematopoietic recovery occurred in 22 of 23 patients with a median time to an absolute neutrophil count (ANC)z500/pL of 21 days. Donor cell engraftment was subsequently verified by cytogenetic andlor DNA EPLETION OF T lymphocytes from the bone marrow D (BM) allograft has resulted in a significant decrease in the incidence and severity of acute graft-versus-host disease (GVHD) in both animal models and man.'.* The methods of ex vivo lymphocyte depletion, however, are varied; they include lectin-separation followed by sheep erythrocyte r o~e t t i n g ,~.~ anti-T lymphocyte monoclonal antibodies with or without conjugated immunomagnetic spheres," methylprednisolone,lZ and counterflow centrifugal elutriation (CCE).'3*i4 It has yet to be determined if any one methodology is clearly better than the others.
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We have previously reported the results of our preclinical and clinical studies using a three-flow rate CCE procedure for lymphocyte-depleting allogeneic BM before transplantation. 13.15. 16 Having shown that the CCE procedure success-analysis in all of 21 evaluable patients. No patient developed systemic acute GVHD. Only five (22%) developed cutaneous GVHD (clinical stage 1) that required steroid treatment, including one patient who failed to engraft. The median follow-up of the patients enrolled in this study is 14 months (range, 5 to 20 months). Actuarial survival 1 year after BMT is 83%. Thus, in two consecutive clinical trials using CCE to deplete donor BM of alloreactive lymphocytes (1.0 x 10' versus 0.5 x I O 6 lymphocytes/kg), we have demonstrated that the procedure does not interfere with BM engraftment and is effective in decreasing the incidence and severity of acute GVHD. Furthermore, comparison of these studies has revealed a differential dose response relationship between the number of graft lymphocytes, protection of engraftment, and induction of acute GVHD. Although there appears to be a modest relationship between lymphocyte dose and time to hematopoietic recovery, the 50% reduction in lymphocyte dose from that used in our previous trial resulted in a marked decrease in acute GVHD without compromising engraftment. 0 1990 by The American Society of Hematology.
fully separated alloreactive lymphocytes from the marrow blasts and clonogenic cells, we initiated a clinical trial to evaluate the toxicities of CCE, the most important being interference with engraftment. In this first phase I clinical trial in which all patients received 1 x lo6 lymphocytes per kilogram ideal body weight (IBW) and cyclosporine A (CsA) immunosuppression for 170 days after bone marrow transplantation (BMT), we demonstrated that there was (1) no detectable cell loss or damage; (2) greater than 98% cellular viability in all fractions; (3) greater than 90% recovery of hematopoietic colony forming cells; (4) a low incidence (2.5%) of bacterial contamination during BM processing; and (5) prompt hematopoietic recovery in 38 of 40 patients. Although the procedure appeared to reduce the severity of acute GVHD in this older patient population (mean age, 39 years), the overall incidence of acute GVHD (65%) was not appreciably affected. Except for three patients who actually received fewer lymphocytes than the planned 1.0 x 106/kg IBW, ail patients predicted to develop acute GVHD by our skin explant model" did so. Using the same cell separation methodology and posttransplant immunosuppression regimen, we now report the results of a phase 1-11 clinical trial in which all patients received CCE-separated BM containing 0.5 x lo6 lymphocytes per kilogram IBW.
METHODS
Informed consent. The protocols for marrow fractionation by CCE and intensive myeloblative therapy before transplantation were reviewed and approved by the Joint Committees on Clinical Investigation (JCCI) of The Johns Hopkins Medical Institutions. Informed consent was obtained from all patients.
The semi-closed elutriation system was evaluated by the JCCI for use in each of the clinical trials. A Food and Drug Administration (FDA) investigational device exemption as a nonsignificant risk device was issued on the basis of its approval by the JCCI.
Patient eligibility.
The candidates for this pilot study were limited to those with acute myelogenous leukemia (AML) and acute lymphoblastic leukemia (ALL) in complete remission (CR), chronic myelogenous leukemia (CML) in chronic phase (CP), or Hodgkin's disease (HD) and non-Hodgkin's lymphoma (NHL) in CR, partial remission (PR), or relapse with resistant (RES) disease18 between the ages of 31 and 55 years. Within this population, patients considered to be at low risk for developing acute GVHD on the basis of the results of our skin explant assay were excluded. Technical aspects of this skin explant model have been detailed elsewhere."
Twenty-three patients were enrolled in the study; nine patients had CML in CP, seven patients had AML (six CRl, one CR2); three had ALL (two CR1, one CR2); one had nodular sclerosing HD (one PR2); and three had NHL (one CR3, two RES) ( Table 1) . Sixteen of the twenty-three patients were skin explant positive and thus predicted to develop acute GVHD. The remaining seven patients either refused the skin explant test (N= 1). could not be scheduled for the skin explant test (N=2), or had skin explants that were technically unevaluable (ie, inadequate biopsy specimen or bacterial/ fungal contamination; N=4). Three patients who were otherwise eligible on the basis of age and disease status were excluded because of conclusive negative results in the skin explant assay.
Transplantation procedure. All sibling marrow donors were genotypically HLA-A, B, C, and D/DR identical with the recipients. Marrow aspiration was performed under general or epidural anesthesia in the operating room. The mean number of nucleated cells harvested was 4.7 x 108/kg recipient IBW (range, 3.1 to 6.5 x 108/kg). After marrow processing, the mean number of marrow cells infused was 0.9 x 108/kg recipient IBW (range 0.6 to 1.5 x 108/kg).
The pretransplant preparative regimen was determined by the patients' admission diagnosis. All patients with CML, ALL, HD, and two of three patients with NHL received cyclophosphamide (CY) 50 mg/kg IBW per dose intravenously (IV) on days -8, -7, -6, and -5; and total body irradiation (TBI) at 300 cGy/d on days -4, -3, -2, and -1 (with lung shielding on day -2). These patients underwent BMT 24 hours after the last dose of irradiation. Patients with AML received busulfan (BU) 1 mg/kg IBW per dose orally (PO) every 6 hours for 16 doses on days -9, -8, -7, and -6, followed by CY 50 mg/kg IBW per dose IV on days -5, -4, -3, and -2, with marrow rescue 48 hours after the last dose of CY. One patient (UPN 938) with RES NHL received BU 1 mg/kg per dose PO every 6 hours on days -8, -7, -6, and -5; etoposide (VP-16) 20 mg/kg over 24 hours by continuous IV infusion on day -4; and CY 60 mg/kg IBW IV on days -3 and -2. BMT was performed on day 0. As in the initial clinical trial," all patients received CsA immunosuppressive therapy beginning 2 days before marrow infusion at a dose of 5 mg/kg IBW IV. The CsA dose was tapered to 3.75 mg/kg IV on days 3 through 14 and to 2.5 mg/kg IV on days 15 through 21. On days 22 through 26, the CsA was given both IV at 1.5 mg/kg and PO at 5 mg/kg. Between days 27 and 50, the patients received CsA 10 mg/kg PO, which was subsequently tapered to 7.5 mg/kg. CsA immunosuppressive therapy was discontinued on day 170.
Peritransplant supportive care given to these patients has previously been reported." Patients seropositive for Herpes simplex and/or cytomegalovirus (CMV) received prophylactic acyclovir IV (250 and 500 mg/m2, respectively, every 8 hours) from day -4 until the day of discharge from the inpatient unit." When the absolute neutrophil count (ANC) fell below 500/pL, reverse isolation procedures were used. Broad spectrum antibiotics were given for fever during aplasia, and amphotericin B was added for documented systemic fungal infections or for persistent fever unresponsive to antibiotic therapy. Platelet transfusions were given when platelet count fell below 20 x 106/pL, and packed red blood cells were given to maintain a hematocrit above 30%.
Staging and treatment of acute GVHD. The Johns Hopkins criteria for staging acute GVHD are described in Table 2 . '' In this study, all patients were evaluated daily for signs of acute GVHD. No patient had greater than overall clinical stage 1 disease. Patients having overall clinical stage 0 disease (ie, histopathologic grade 2 Supportive care. cutaneous disease involving less than 25% of the total body surface without hepatic or gastrointestinal disease) were observed or treated with topical steroids. Patients having stage 1 disease (ie, histopathologic grade 2 cutaneous disease involving greater than 25% of the total body surface without hepatic or gastrointestinal disease) were treated with systemic steroids. Methylprednisolone (2.5 mg/kg) was given for 4 days, after which the dose was tapered (0.5 mg/kg) every 4 days. A detailed description of the separation methodology used in this study has been published elsewhere.2' Briefly, bone marrow buffy coat cells (44.3 + 8.3% [mean SD] of the harvested nucleated marrow cells), were prepared on a Haemonetics Model 30 (Braintree, MA).22 They were loaded into a Beckman JE-1OX elutriation rotor and chamber (a gift from Beckman Instruments, Palo Alto, CA) at a total flow rate of 70 mL/min, rotor speed 1.26 x IO3 x g and temperature of 2OOC. The elutriation medium:' compounded by Caremark Pharmacy Services (Columbia, MD), was tested for sterility and absence of endotoxin. After the cells were loaded into the chamber, the medium flow rate was raised to 110 mL/min with the rotor speed held constant. The small-sized cells were eluted to exhaustion. Subsequently, the flow rate was raised to 140 mL/min, where intermediate-sized cells were collected. The cells remaining in the chamber were collected by continuing medium flow after stopping the rotor (designated the rotor-off [R/O] fraction). The lymphocyte depleted R/O fraction (mean volume 367 mL; range, 299 to 425 mL) was immediately issued to the BMT unit and infused without additional filtration.
Differential counts on 500 cells (250 cells counted independently by two people) were performed on Wright-Giemsa stained cytocentrifuge preparations. The dose of lymphocytes given in the R/O fraction was determined, and the volume of 140 mL/min fraction necessary to obtain a total dose of 0.5 x lo6 lymphocytes/kg recipient IBW was calculated. The volume of this preparation was reduced by centrifugation if it exceeded 300 mL. In two instances (UPN 922 and 938) , the R/O fraction was the sole fraction given to the patient since it contained greater than 0.5 x lo6 lymphocytes/kg IBW (0.65 and 0.55 x lo6 lymphocytes/kg, respectively). In one instance, the entire 140 mL/min fraction and a small portion of the 110 mL/min fraction was infused (UPN 1033) to obtain a total of 0.5 x lo6 lymphocytes/kg IBW. The lymphocyte-containing fraction was issued separately and given as described above. Overall, the mean total volume of marrow infused was 514 mL (range, 368 to 68 1 mL). Graft formulation and recovery calculations were aided by the use of a computer spreadsheet that tabulated fraction volumes and CCE procedure.
absolute and differential cell counts. Sterility tests ('4C-labeled tryptic soy broth) were performed on the unseparated bone marrow and marrow graft after CCE.
Granulocyte/monocyte colony forming units (CFU-GM) were assayed using a methylcellulose culture system.23 Colonies were scored on day 14.
Event times were measured from the date of BMT to date of acute GVHD, relapse, death, or last follow-up examination. Date and stage of acute GVHD was determined by the GVHD team. Disease-free survival (DFS) is defined as time until death or relapse; survival is defined as time until death. Event times were analyzed as of August 20, 1989.
The probabilities of survival, DFS, and remaining in remission were estimated by the method of Kaplan and Meier24 using the SAS Lifetest proced~re.~' Colony assays.
Srarisrical merhods.

RESULTS
Clinical characteristics.
Twenty-three consecutive patients meeting the criteria outline above were enrolled in the study between January, 1988 and March, 1989. The clinical characteristics of the 23 patients enrolled in the study are described in Table 1 . Median patient age was 39 years (range, 33 to 50 years) and median donor age was 38 years (range, 20 to 57 years). The male to female ratio was 1.9:l. Of the 23 patients, 16 were predicted to develope acute G V H D on the basis of the skin explant model and 7 had explants that were considered unevaluable.
The cellular composition of the marrow allograft is shown in Table 3 . T h e grafts were composed of the entire R/O fraction (N=23), a portion of the 140 mL/min fraction ( N = 2 1 ) , and a portion of the 110 mL/min fraction ( N = l ) . Finally, the total number of nucleated cells, blasts and CFU-GM in the graft fraction of the one patient (UPN 996) who never demonstrated any evidence of hematopoietic recovery was 6.7 x lo9 (1.0 x 10'per kg), 1.5 x lo8 (2.7 x lo6 per kg), and 2.1 x lo7 (3.0 x lo5 per kg), respectively. All graft preparations were evaluated for sterility three times during the procedure: after (1) harvesting the marrow, (2) preparing the marrow buffy coat, and (3) completing the elutriation. Eighteen remained sterile throughout all phases of the procedure, four were contaminated during the harvesting procedure (three Staphylococcus epidermidis, one Corynebacterium species), and one was contaminated during the buffy coating procedure (one S epidermidis). However, no evidence of bacterial or fungal contamination was noted in any of the 23 grafts after the elutriation procedure.
The time to hematopoietic recovery for the 23 patients is shown in Table 1 . With the exception of the one patient who failed to demonstrate any evidence of recovery, the median time to white blood cell count (WBC) r1,000/pL was 20.5 days (range, 11 to 40 days), an ANC rSOO/pL was 21.0 days (range, 16 to 45 days), and a transfusion-independent platelet count r50,000/pL was 40.5 days (range, 17 to >lo0 days). Of the five patients who did not exhibit a platelet count r50,000/pL before outpatient clinic discharge (day 100 after BMT), all eventually recovered by the subsequent follow-up examination (6 months). Three of these five patients with delayed platelet recovery had anti-platelet antibody demonstrated at one or more times after BMT.
Engraftment of donor cells was assessed by cytogenetic analysis and/or restriction fragment length polymorphism (RFLP) of the bone marrow in 22 patients and confirmed in 21 patients. Eight patients had evidence of mixed chimerism by RFLP analysis of BM aspirates. Of these patients, four showed only transient evidence of host derived hematopoietic cells, two appear to have a stable mixture (approximately 50%/50%) of donor and host derived cells, and two continue to show a progressive increase in the proportion of host cells. The one patient (UPN 996) who failed to engraft on the basis of the bone marrow (aspirate and biopsy) evaluation 28 days after BMT had too few cells in the BM to be evaluated by cytogenetic and/or RFLP analysis before second marrow transplant. After second BMT with unprocessed marrow, donor cell engraftment was confirmed.
Sixteen patients were predicted to develop acute Engraftment.
GVHD.
GVHD based on the results of our skin explant model. Of 23 patients transplanted, five were treated for acute GVHD. All five responded and no patient had organ involvement ( Figure 1 ). All cases of acute GVHD were diagnosed between days 7 and 22 after BMT. Of note, only one patient (UPN 942) has developed chronic GVHD thus far.
Complications and survival. BMT-related complications and the status of each patient as of August 20,1989 are shown in Table 4 . Besides the occurrence of clinically significant acute and chronic GVHD (ie, disease requiring treatment) in five patients, BMT-related complications were limited to infectious complications (N = 9), reversible renal insufficiency (ie, serum creatinine 22.2 mg/dL, N=2), hepatic veno-occlusive disease (VOD, N = l), failure of engraftment (N = l), idiopathic interstitial pneumonitis (IIP, N = l), and cytogenetic and/or hematologic disease relapse (N= 6). Although all patients received empiric antibiotic therapy during the period of aplasia, three patients had documented bacterial sepsis. Five patients had CMV sepsis, with one of the five subsequently developing CMV pneumonitis. Although evidence of viral inclusions were seen on bronchial washings, cultures remained negative. The patient survived without therapy. One additional patient developed a pulmonary cavitary lesion that was presumed to be Aspergillus; the lesion responded to treatment with amphotericin B.
To date, six patients have relapsed (Table 3) . Three patients had C M L in CP, one patient had AML in CRl, one patient had ALL in CR2, and one patient had RES NHL. Of the three patients with C M L relapse, one patient (UPN 956) never achieved a complete cytogenetic remission by DNA analysis and evidenced hematologic relapse on day 167; one patient (UPN 922) had concurrent cytogenetic and hematologic relapse; and one patient (UPN 982) had only cytogenetic evidence of disease (days 83 to 270 after BMT) but is now negative 334 days after BMT by both bcr and karyotypic analyses. These patients underwent allogeneic BMT 78, 21, and 13 months after diagnosis, respectively. Of the other three patients with relapse, one patient (UPN 935) died of disease, one patient (UPN 944) achieved a second remission with non-myeloablative doses of chemotherapy, and one patient (UPN 938) with N H L has remained free of disease 9 months after receiving mediastinal irradiation.
The overall survival for all patients entered on this study is currently 83% (SE *8%) with a median follow-up of 417 days (range, 162 to 592 days). The actuarial disease-free survival at 1 year is 52% (SE 13%)(Fig 2) . The causes of death in the current study were interstitial pneumonitis ( N = l ) , VOD ( N = l ) , failure to engraft (N=l), and disease relapse ( N = 1).
DISCUSSION
In our first clinical trial using elutriation to deplete lymphocytes from BM allograft^,'^*^^ we demonstrated the procedure's lack of stem cell toxicity. Although the severity of acute GVHD appeared to be reduced, the overall incidence (65%) was unaffected. In the present study we report that a small modification in our elutriation protocol resulted in the complete elimination of systemic acute GVHD without compromising engraftment. The present study differs from the first in only two respects: (1) patient eligibility was based on the result of our skin explant assay, and (2) In the present study the median time to ANC r 5 0 0 /~L was 2 1 days. This compares with 18 days for recipients of 1 x lo6 lymphocytes/kg IBW and 17 days for a group of recipients who received unmanipulated BM and matched for disease, age, and both CsA and preparative regimens.27 Delayed platelet recovery was more pronounced in this study with a median time to platelet counts r50,000/pL of 41 days (29 days in the previous elutriation trial and 22 days in matched controls). Although there appears to be a modest relationship between lymphocyte dose and time to hematopoietic recovery, the proportion of patients with donor cell engraftment was identical (95% and 96%) in the two elutriation trials. In contrast, we found a steep relationship between lymphocyte dose and incidence and severity of acute GVHD. By reducing the lymphocyte dose by half, we significantly decreased the actuarial incidence of acute GVHD (clinical stage 0 to 4) from 65% to 30% (P < .01, Wilcoxon score). While five patients (1 3%) entered onto the first trial developed visceral GVHD (clinical stage 2 to 4), no patient on the current trial did so. These results are particularly significant in view of the patient selection criteria. In both studies patients were at increased risk of acute GVHD morbidity by virtue of age (median, 39 years). However, of the 23 patients entered in the present study, 16 were skin explant assay positive with a 5.7-fold higher relative risk of developing acute GVHD17 than patients who are skin explant assay negative.
Bacterial contamination was documented only once after marrow buffy coating and at no time after CCE. Taken together with the data from our previous studies, 59 of 60 
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preparations that were culture negative before elutriation remained negative. Thus, it appears that CCE does not impose any additional risk of bacterial or fungal contamination to the marrow graft. The incidence of transplant-related complications (ie, GVHD, VOD, infection, and interstitial pneumonitis) was low. Comparing the first and second trials, acute GVHD (as cause of death) occurred in 13% versus 0%, chronic GVHD (as cause of death) in 5% versus 0%, VOD in 3% versus 5%, fatal infection in 10% versus 096, and interstitial pneumonitis in 10% versus 5%. Thus, by virtue of its efficacy in GVHD prevention, CCE may have indirectly decreased the risk of chonic GVHD, fatal infections and interstitial pneumonitis since these complications are associated with acute GVHD and/or its therapy. The actuarial survival at 100 days and 1 year after BMT (87% and 83%, respectively) reflect the decrease in early transplant mortality.
Disease relapse, on the other hand, is a significant cause of treatment failure. The actuarial probability of remaining in remission for patients receiving elutriated BM containing 0.5 x lo6 lymphocytes per kg IBW is 60% (SE 14%) at 1 year after BMT. However, the follow-up in the present study is limited and additional patients may relapse. As noted by other investigators, the risk of relapse after transplantation with lymphocyte-depleted BM is most marked in patients with CML.28*29 Of the 15 CML-CP patients receiving elutriated BM (0.5 or 1.0 x lo6 lymphocytes per kg) who survived 1 year or relapsed within the first year, 53% have experienced a cytogenetic relapse alone ( N = l ) or cytogenetic and hematologic relapse (N = 7). The median time to cytogenetic and/or hematologic relapse in these patients is 1 year (range, 83 to 620 days). Of the four patients first diagnosed by cytogenetic but not hematologic criteria, three have progressed to hematologic relapse and one has reverted (Phl and bcr negative).
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In conclusion, we have found that CCE provides a technically simple, safe, and efficacious means for depleting bone marrow of alloreactive lymphocytes. While a variety of methods are available for lymphocyte depletion, CCE does not rely on negative selection; CCE allows the investigator to retrieve virtually all marrow cells loaded into the elutriator without apparent functional alteration. Even cell populations depleted from the marrow graft are readily available for further study and manipulation. Because this method of cell separation is particularly suited for studying cell subpopulations, we are attempting to identify and characterize the effector cell(s) responsible for the graft-versus-leukemia effect. 30 It is hoped that these results will help guide future trials in which specific lymphoid and non-lymphoid cell subpopulations with defined anti-tumor activity will replace the current method of adding back portions of lymphocyterich fractions separated solely on the basis of physical properties.
